Samantha J McClenahan1, Michael D Hambuchen1, Christy M Simecka2, Melinda G Gunnell1, Michael D Berquist1, S Michael Owens3. 1. Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA. 2. Division of Laboratory Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA. 3. Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA. Electronic address: mowens@uams.edu.
Abstract
BACKGROUND: 3,4-methylenedioxypyrovalerone (MDPV) toxicity includes intense neurological and cardiovascular events. We examined MDPV-induced cardiovascular, temperature, and locomotor effects following escalating and repeated MDPV administration in adult male and female Sprague-Dawley rats and compared these effects to cocaine in male rats. METHODS: Telemetry devices were surgically implanted to allow continuous measurement of cardiovascular, temperature, and locomotor activity over a 22 h period after dosing. Rats were administered increasing intraperitoneal (IP) MDPV doses (1-5.6 mg/kg) every other day, followed two days later by a binge regimen of four injections of 3 mg/kg MDPV at 2 h intervals. MDPV serum concentrations were measured by LC-MS/MS. Cocaine (3-30 mg/kg) and four injections of 30 mg/kg IP were administered to male rats for comparison with male MDPV data. RESULTS: The duration of MDPV cardiovascular effects was significantly greater (p < 0.05) in male rats than female rats at 3-5.6 mg/kg. The ED50 for MDPV-induced locomotor was significantly lower in males (2.4 ± 0.3) than females (3.4 ± 0.2). Males showed significantly greater variability in MDPV serum concentrations than females after binge dosing. MDPV produced five-fold more potent cardiovascular effects than cocaine in male rats. MDPV did not alter thermoregulation in either sex, but cocaine binge administration decreased temperature. CONCLUSION: Effects of MDPV on temperature were not significantly different between sexes. MDPV-induced cardiovascular and locomotor effects in males lasted significantly longer and were more potent than in females. These differences appeared to be related to pharmacokinetic factors leading to greater variance in MDPV serum concentrations in males.
BACKGROUND: 3,4-methylenedioxypyrovalerone (MDPV) toxicity includes intense neurological and cardiovascular events. We examined MDPV-induced cardiovascular, temperature, and locomotor effects following escalating and repeated MDPV administration in adult male and female Sprague-Dawley rats and compared these effects to cocaine in male rats. METHODS: Telemetry devices were surgically implanted to allow continuous measurement of cardiovascular, temperature, and locomotor activity over a 22 h period after dosing. Rats were administered increasing intraperitoneal (IP) MDPV doses (1-5.6 mg/kg) every other day, followed two days later by a binge regimen of four injections of 3 mg/kg MDPV at 2 h intervals. MDPV serum concentrations were measured by LC-MS/MS. Cocaine (3-30 mg/kg) and four injections of 30 mg/kg IP were administered to male rats for comparison with male MDPV data. RESULTS: The duration of MDPV cardiovascular effects was significantly greater (p < 0.05) in male rats than female rats at 3-5.6 mg/kg. The ED50 for MDPV-induced locomotor was significantly lower in males (2.4 ± 0.3) than females (3.4 ± 0.2). Males showed significantly greater variability in MDPV serum concentrations than females after binge dosing. MDPV produced five-fold more potent cardiovascular effects than cocaine in male rats. MDPV did not alter thermoregulation in either sex, but cocaine binge administration decreased temperature. CONCLUSION: Effects of MDPV on temperature were not significantly different between sexes. MDPV-induced cardiovascular and locomotor effects in males lasted significantly longer and were more potent than in females. These differences appeared to be related to pharmacokinetic factors leading to greater variance in MDPV serum concentrations in males.
Authors: Charles W Schindler; Eric B Thorndike; Masaki Suzuki; Kenner C Rice; Michael H Baumann Journal: Br J Pharmacol Date: 2016-11-16 Impact factor: 8.739
Authors: William E Fantegrossi; Brenda M Gannon; Sarah M Zimmerman; Kenner C Rice Journal: Neuropsychopharmacology Date: 2012-11-08 Impact factor: 7.853
Authors: Heather E King; Alison Wakeford; William Taylor; Bradley Wetzell; Kenner C Rice; Anthony L Riley Journal: Pharmacol Biochem Behav Date: 2015-07-26 Impact factor: 3.533
Authors: Chloe J Jordan; Bree A Humburg; Eric B Thorndike; Anver Basha Shaik; Zheng-Xiong Xi; Michael H Baumann; Amy Hauck Newman; Charles W Schindler Journal: J Pharmacol Exp Ther Date: 2019-09-27 Impact factor: 4.030
Authors: Katharine H Nelson; Hayley N Manke; Aikerim Imanalieva; Kenner C Rice; Anthony L Riley Journal: Pharmacol Biochem Behav Date: 2019-08-21 Impact factor: 3.533
Authors: Katharine H Nelson; Hayley N Manke; Jacob M Bailey; Anna Vlachos; Karina J Maradiaga; Shihui Huang; Tania D Weiss; Kenner C Rice; Anthony L Riley Journal: Pharmacol Biochem Behav Date: 2021-10-08 Impact factor: 3.533
Authors: Ana Margarida Araújo; Márcia Carvalho; Vera Marisa Costa; José Alberto Duarte; Ricardo Jorge Dinis-Oliveira; Maria de Lourdes Bastos; Paula Guedes de Pinho; Félix Carvalho Journal: Arch Toxicol Date: 2020-11-19 Impact factor: 5.153